A comparison of total hospital costs for percutaneous coronary intervention patients receiving abciximab versus tirofiban

Catheterization and Cardiovascular Interventions

Volumn 54, Issue 2, 2001, Pages 152-157

  McCollam, Patrick L ^a   Lage, Maureen J ^b   Bala, Mohan ^a  

^a ELI LILLY AND COMPANY   (United States)

^b CENTOCOR INC   (United States)

Author keywords

Glycoprotein IIb IIIa antagonists; Hospital costs; Multivariate analysis; Retrospective study; Sample selection model

Indexed keywords

ABCIXIMAB; TIROFIBAN;

ADULT; AGED; ARTICLE; CORONARY STENT; COST BENEFIT ANALYSIS; COST CONTROL; DATA BASE; DRUG COST; FEMALE; HEALTH INSURANCE; HIGH RISK PATIENT; HOSPITAL BILLING; HOSPITAL COST; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MALE; MODEL; MONEY; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; SAMPLING; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CORONARY DISEASE; FEMALE; HEALTH STATUS; HOSPITAL COSTS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INSURANCE, HEALTH; LENGTH OF STAY; MALE; MIDDLE AGED; MODELS, ECONOMETRIC; PLATELET AGGREGATION INHIBITORS; TYROSINE;

EID: 0034785973     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.1257     Document Type: Article

References (32)

1. Randomized comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (BENESTENT II)
2. In-hospital and one-year economic outcomes after coronary stenting or balloon angioplasty: Results from a randomized clinical trial
3. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high risk coronary angioplasty
4. Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: Results from the EPILOG trial
5. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicenter randomized trial
6. Economic impact of GP IIb/IIIa blockade after high-risk angioplasty
7. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes
8. Economics of glycoprotein IIb/IIIa inhibition
9. Abciximab provides cost effective survival advantage in high volume interventional practice
10. Abciximab in unstable coronary syndromes: Benefits and costs in a group model non-profit HMO
11. Abciximab: A pharmacoeconomic review of its use in percutaneous coronary revascularization
12. Shorter hospital length of stay for coronary angioplasty patients who receive abciximab
13. Shorter hospital length of stay in managed care patients undergoing coronary angioplasty who receive abciximab
14. Shorter intensive care unit stay for coronary angioplasty patients who receive abciximab
15. Impact of abciximab versus tirofiban on hospital length of stay for PCI patients
16. Generalized models with selectivity
17. Sample selection as a specification error
18. Health care costs and outcomes: How should we evaluate real world data?
19. Estimating endogenous treatment effects in retrospective data analysis
20. Methods for using large databases in health care research: Problems and promises - Proceedings of the Third Biennial Regenstrief Conference
21. SSRI antidepressant selection and concomitant prescribing of anxiolytics and sedative-hypnotics: Evidence from primary care in the United Kingdom
22. Issues in the analysis of selectivity bias
23. Refinement of the medicare diagnosis-related groups to incorporate a measure of severity
24. Regional variation across the United States in the management of acute myocardial infarction
25. Payer status and the utilization of hospital resources in acute myocardial infarction
26. Clinical correlates of the initial and long-term cost of coronary bypass surgery and coronary angioplasty
27. Acute and long-term cost implications of coronary stenting
28. Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? analysis using instrumental variables
29. Health care costs and outcomes: How should we evaluate real world data?